);

   

Research and Development Pipeline

Oyster Point’s initial R&D focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the parasympathetic nervous system (PNS) via the trigeminal nerve. The PNS is part of the involuntary nervous system responsible for regulating homeostasis, the “rest and digest” system and is an important pathway for basal tear film formation. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production in patients with Dry Eye Disease.

The two lead compounds, OC-01 and OC-02, are highly selective nAChR agonists and are being developed for the treatment of signs and symptoms of Dry Eye Disease. The innovative therapy is developed to leverage the Trigeminal Parasympathetic Pathway (TPP) to activate the glands that comprise the lacrimal functional unit (LFU) and promote tear film production. These compounds are being developed in a nasal spray vs. topical eye drop. Utilization of a nasal spray facilitates a convenient access into the nasal cavity, targeting local delivery of the drug compound to activate the Trigeminal Parasympathetic Pathway (TPP), promoting tear film production.

OC-01 and OC-02 are currently in Phase 2 trials to evaluate their potential as treatments for the signs and symptoms of Dry Eye Disease (DED). Both candidates have been well-studied in other disease areas, allowing for the rapid advancement of clinical trials. Evaluating the compounds in parallel offers Oyster Point the opportunity to determine which compound offers the better product profile and increases the likelihood of regulatory and commercial success.